{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T20:29:12Z","timestamp":1786825752093,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104476"],"award-info":[{"award-number":["82104476"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.intimp.2022.109589","type":"journal-article","created":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T23:14:09Z","timestamp":1671405249000},"page":"109589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer"],"prefix":"10.1016","volume":"114","author":[{"given":"Yamin","family":"Shu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiling","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qilin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2022.109589_b0005","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians 2021, 71(3): 209-249.","DOI":"10.3322\/caac.21660"},{"key":"10.1016\/j.intimp.2022.109589_b0010","doi-asserted-by":"crossref","unstructured":"Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, Kramer J, Siegel RL. Cancer treatment and survivorship statistics, 202CA: a cancer journal for clinicians 2022.","DOI":"10.3322\/caac.21731"},{"issue":"6","key":"10.1016\/j.intimp.2022.109589_b0015","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/annonc\/mdr487","article-title":"Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer","volume":"23","author":"Hayashi","year":"2012","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology"},{"issue":"23","key":"10.1016\/j.intimp.2022.109589_b0020","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1200\/JCO.2012.47.1102","article-title":"PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer","volume":"31","author":"Paz-Ares","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2022.109589_b0025","unstructured":"National Comprehensive Cancer Network. Non-small cell lung cancer (version 3. 2022) [Internet]. [updated March 16, 2022]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl_blocks.pdf."},{"key":"10.1016\/j.intimp.2022.109589_b0030","unstructured":"Zhou. C, Wang. J, Wang. B, Cheng. Y. Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2020 Version). Chin J Lung Cancer, 24(4): 217-235."},{"issue":"17","key":"10.1016\/j.intimp.2022.109589_b0035","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.intimp.2022.109589_b0040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41577-020-0275-8","article-title":"Dissecting the mechanisms of immune checkpoint therapy","volume":"20","author":"Sharma","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"16","key":"10.1016\/j.intimp.2022.109589_b0045","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.intimp.2022.109589_b0050","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamaoncol.2018.4604","article-title":"Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma: A Review","volume":"5","author":"George","year":"2019","journal-title":"JAMA Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2022.109589_b0055","doi-asserted-by":"crossref","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol."},{"issue":"10272","key":"10.1016\/j.intimp.2022.109589_b0060","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"21","key":"10.1016\/j.intimp.2022.109589_b0065","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2022.109589_b0070","article-title":"First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients","volume":"7","author":"O'Byrne","year":"2022","journal-title":"ESMO open"},{"key":"10.1016\/j.intimp.2022.109589_b0075","unstructured":"Opdivo\u00ae (Nivolumab) - ONO PHARMACEUTICAL CO., LTD. Ono Pharmaceutical Co. Ltd. Available at https:\/\/www.ono-pharma.com\/sites\/default\/files\/en\/news\/press\/sm_cn201217.pdf. Published 2020. Accessed December 17, 2020."},{"key":"10.1016\/j.intimp.2022.109589_b0080","unstructured":"Opdivo\u00ae (Nivolumab) - ONO PHARMACEUTICAL CO., LTD. Ono Pharmaceutical Co., Ltd. Available at https:\/\/www.ono-pharma.com\/sites\/default\/files\/en\/news\/press\/enews20210226_2.pdf. Published 2021. Accessed February26, 2021."},{"key":"10.1016\/j.intimp.2022.109589_b0085","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.830380","article-title":"Cost-Effectiveness of Tislelizumab Versus Docetaxel for Previously Treated Advanced Non-Small-Cell Lung Cancer in China","volume":"13","author":"Gong","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109589_b0090","doi-asserted-by":"crossref","first-page":"e210037","DOI":"10.1001\/jamanetworkopen.2021.0037","article-title":"Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma","volume":"4","author":"Su","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"3","key":"10.1016\/j.intimp.2022.109589_b0095","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-O","article-title":"Development of WHO guidelines on generalized cost-effectiveness analysis","volume":"9","author":"Murray","year":"2000","journal-title":"Health Econ."},{"key":"10.1016\/j.intimp.2022.109589_b0100","unstructured":"National Bureau of Statistics of China. Available at: http:\/\/www.stats.gov.cn\/xxgk\/jd\/sjjd2020\/202202\/t20220228_1827972.html (Accessed April 06, 2022)."},{"key":"10.1016\/j.intimp.2022.109589_b0105","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1471-2288-11-139","article-title":"Improved curve fits to summary survival data: application to economic evaluation of health technologies","volume":"11","author":"Hoyle","year":"2011","journal-title":"BMC Med. Res. Method."},{"issue":"1","key":"10.1016\/j.intimp.2022.109589_b0110","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12942-021-00276-y","article-title":"Efficiency of fine scale and spatial regression in modelling associations between healthcare service spatial accessibility and their utilization","volume":"20","author":"Gao","year":"2021","journal-title":"Int. J. Health Geogr."},{"key":"10.1016\/j.intimp.2022.109589_b0115","unstructured":"National Bureau of Statistics. National data of National Bureau of Statistics in 2020. Available from: https:\/\/data.stats.gov.cn\/tablequery.htm?code=AD02. Accessed June 18, 2021."},{"key":"10.1016\/j.intimp.2022.109589_b0120","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.851522","article-title":"Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer\/Gastroesophageal Junction Cancer\/Esophagel Adenocarcinoma in China","volume":"12","author":"Shu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2022.109589_b0125","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.728440","article-title":"Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer in China","volume":"12","author":"Qiao","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2022.109589_b0130","doi-asserted-by":"crossref","first-page":"8297","DOI":"10.2147\/CMAR.S334643","article-title":"Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China","volume":"13","author":"Shu","year":"2021","journal-title":"Cancer Manag. Res."},{"issue":"3","key":"10.1016\/j.intimp.2022.109589_b0135","doi-asserted-by":"crossref","first-page":"e32530","DOI":"10.1371\/journal.pone.0032530","article-title":"Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting","volume":"7","author":"Wu","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.intimp.2022.109589_b0140","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2217\/cer-2017-0069","article-title":"Health state utilities in patients with advanced non-small-cell lung cancer in China","volume":"7","author":"Shen","year":"2018","journal-title":"J. Comp. Eff. Res."},{"issue":"5","key":"10.1016\/j.intimp.2022.109589_b0145","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1111\/ajco.12477","article-title":"Health state utilities in non-small cell lung cancer: An international study","volume":"13","author":"Nafees","year":"2017","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2022.109589_b0150","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.573852","article-title":"Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer","volume":"12","author":"Hao","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2022.109589_b0155","unstructured":"National Bureau of Statistics of China. Available at: https:\/\/data.stats.gov.cn\/."},{"key":"10.1016\/j.intimp.2022.109589_b0160","series-title":"Guide to the Methods of Technological Appraisal","author":"National Institute for Health and Care Excellence","year":"2013"},{"issue":"5","key":"10.1016\/j.intimp.2022.109589_b0165","doi-asserted-by":"crossref","first-page":"e218787","DOI":"10.1001\/jamanetworkopen.2021.8787","article-title":"Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer","volume":"4","author":"Courtney","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.intimp.2022.109589_b0170","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.760686","article-title":"Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer","volume":"11","author":"Yang","year":"2021","journal-title":"Front. Oncol."},{"issue":"14","key":"10.1016\/j.intimp.2022.109589_b0175","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2217\/imt-2020-0112","article-title":"Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC","volume":"12","author":"Li","year":"2020","journal-title":"Immunotherapy"},{"issue":"7","key":"10.1016\/j.intimp.2022.109589_b0180","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s40261-022-01168-0","article-title":"Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan","volume":"42","author":"Mo","year":"2022","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.intimp.2022.109589_b0185","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.580459","article-title":"Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer","volume":"12","author":"Wan","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109589_b0190","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1080\/13696998.2022.2077549","article-title":"Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States","volume":"25","author":"Berling","year":"2022","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.intimp.2022.109589_b0195","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.3389\/fonc.2020.01649","article-title":"Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer","volume":"10","author":"Hu","year":"2020","journal-title":"Front. Oncol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922010748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922010748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:53:39Z","timestamp":1761587619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922010748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":39,"alternative-id":["S1567576922010748"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109589","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109589","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109589"}}